Fixed duration vs. prolonged duration treatment after first line therapy in patients with systemic light chain amyloidosis

References

• Milani P, Merlini G, Palladini G. Light chain amyloidosis. Mediterr J Hematol Infect Dis. 2018;10(1):e2018022.
   PubMedGoogle Scholar
• Palladini G, Merlini G. What is new in diagnosis and management of light chain amyloidosis? Blood. 2016;128(2):159–168.
   PubMed Web of Science ®Google Scholar
• Nienhuis HL, Bijzet J, Hazenberg BP. The prevalence and management of systemic amyloidosis in Western countries. Kidney Dis. 2016;2(1):10–19.
   Google Scholar
• Bellotti V, Merlini G, Bucciarelli E, et al. Relevance of class, molecular weight and isoelectric point in predicting human light chain amyloidogenicity. Br J Haematol. 1990;74(1):65–69.
   PubMed Web of Science ®Google Scholar
• Muchtar E, Buadi FK, Dispenzieri A, et al. Immunoglobulin light-chain amyloidosis: from basics to new developments in diagnosis, prognosis and therapy. Acta Haematol. 2016;135(3):172–190.
   PubMed Web of Science ®Google Scholar
• Merlini G, Seldin DC, Gertz MA. Amyloidosis: pathogenesis and new therapeutic options. J Clin Oncol. 2011;29(14):1924–1933.
   PubMed Web of Science ®Google Scholar
• Merlini G. AL amyloidosis: from molecular mechanisms to targeted therapies. Hematol Am Soc Hematol Educ Program. 2017;2017(1):1–12.
   PubMed Web of Science ®Google Scholar
• Dispenzieri A, Buadi F, Kumar SK, et al. Treatment of immunoglobulin light chain amyloidosis: Mayo stratification of myeloma and risk-adapted therapy (mSMART) consensus statement. Mayo Clin Proc. 2015;90(8):1054–1081.
   PubMed Web of Science ®Google Scholar
• Wechalekar AD, Gillmore JD, Bird J, et al. Guidelines on the management of AL amyloidosis. Br J Haematol. 2015;168(2):186–206.
   PubMed Web of Science ®Google Scholar
• Comenzo RL, Reece D, Palladini G, et al. Consensus guidelines for the conduct and reporting of clinical trials in systemic light-chain amyloidosis. Leukemia. 2012;26(11):2317–2325.
   PubMed Web of Science ®Google Scholar
• Sanchorawala V, Wright DG, Quillen K, et al. Tandem cycles of high-dose melphalan and autologous stem cell transplantation increases the response rate in AL amyloidosis. Bone Marrow Transplant. 2007;40(6):557–562.
   PubMed Web of Science ®Google Scholar
• McCarthy PL, Holstein SA, Petrucci MT, et al. Lenalidomide maintenance after autologous stem-cell transplantation in newly diagnosed multiple myeloma: a meta-analysis. J Clin Oncol. 2017;35(29):3279–3289.
   PubMed Web of Science ®Google Scholar
• Reece D, Hegenbart U, Sanchorawala V, et al. Long-term follow-up from a phase 1/2 study of single-agent bortezomib in relapsed systemic AL amyloidosis. Blood. 2014; 124(16):2498–2506.
   PubMed Web of Science ®Google Scholar
• Gertz MA, Comenzo R, Falk RH, et al. Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th international symposium on amyloid and amyloidosis, Tours, France, 18–22 April 2004. Am J Hematol. 2005;79(4):319–328.
   PubMed Web of Science ®Google Scholar
• Milani P, Basset M, Russo F, et al. Patients with light-chain amyloidosis and low free light-chain burden have distinct clinical features and outcome. Blood. 2017;130(5):625–631.
   PubMed Web of Science ®Google Scholar
• Lilleness B, Ruberg FL, Mussinelli R, et al. Development and validation of a survival staging system incorporating BNP in patients with light chain amyloidosis. Blood. 2019;133(3):215–223.
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network. Systemic Light Chain Amyloidosis (Version 6); 2019. Available from: https://www.nccn.org/professionals/physician_gls/pdf/amyloidosis.pdf
   Google Scholar
• Gertz MA. Immunoglobulin light chain amyloidosis: 2020 update on diagnosis, prognosis, and treatment. Am J Hematol. 2020;95(7):848–860.
   PubMed Web of Science ®Google Scholar
• Ludwig H, Durie BGM, McCarthy P, et al. IMWG consensus on maintenance therapy in multiple myeloma. Blood. 2012;119(13):3003–3015.
   PubMed Web of Science ®Google Scholar
• Lipe B, Vukas R, Mikhael J. The role of maintenance therapy in multiple myeloma. Blood Cancer J. 2016;6(10):e485.
   PubMedGoogle Scholar
• Morè S, Corvatta L, Maracci L, et al. Developments in consolidation and maintenance strategies in post-remission multiple myeloma. Expert Rev Hematol. 2020;13(4):351–362.
   PubMed Web of Science ®Google Scholar
• Landau H, Hassoun H, Rosenzweig MA, et al. Bortezomib and dexamethasone consolidation following risk-adapted melphalan and stem cell transplantation for patients with newly diagnosed light-chain amyloidosis. Leukemia. 2013;27(4):823–828.
   PubMed Web of Science ®Google Scholar
• Dhodapkar MV, Hussein MA, Rasmussen E, et al. Clinical efficacy of high-dose dexamethasone with maintenance dexamethasone/alpha interferon in patients with primary systemic amyloidosis: results of United States intergroup trial southwest oncology group (SWOG) S9628. Blood. 2004;104(12):3520–3526.
   PubMed Web of Science ®Google Scholar
• Muchtar E, Gertz M, Kumar S, et al. Characterization and prognostic implication of delayed complete response in AL amyloidosis. Eur J Haematol. 2021;106(3):354–361.
   PubMed Web of Science ®Google Scholar
• Jimenez-Zepeda V, Duggan P, Neri P, et al. Bortezomib-maintenance for patients with AL amyloidosis: a single center experience. Blood. 2017;130(Suppl1):3151.
   Google Scholar
• Ozga M, Zhao Q, Benson M, et al. AL amyloidosis: the effects of maintenance therapy on autologous stem cell transplantation outcomes. Blood. 2019;134(Supplement_1):2029–2029.
   Google Scholar
• Sidiqi M, Gertz M. Daratumumab for the treatment of AL amyloidosis. Leuk Lymphoma. 2019;60(2):295–301.
   PubMed Web of Science ®Google Scholar
• Palladini G, Kastritis K, Maurer M, et al. Daratumumab plus CyBorD for patients with newly diagnosed AL amyloidosis: safety run-in results of ANDROMEDA. Blood. 2020;136(1):71–80.
   PubMed Web of Science ®Google Scholar
• Staron A, Burks E, Lee J, et al. Assessment of minimal residual disease using multiparametric flow cytometry in patients with AL amyloidosis. Blood Adv. 2020;4(5):880–884.
   PubMed Web of Science ®Google Scholar
• Kastritis E, Palladini G, Minnema MC, et al. Daratumumab-based treatment for immunoglobulin light-chain amyloidosis. N Engl J Med. 2021;385(1):46–58.
   PubMed Web of Science ®Google Scholar
• Available from: https://clinicaltrials.gov/ct2/show/NCT03201965
   Google Scholar